Community-acquired carbapenem-resistant Acinetobacter baumannii pneumonia in an elderly woman with chronic kidney disease: A case report
Abstract
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a major cause of hospital-acquired infections but is rarely implicated in community-acquired pneumonia (CAP). We report the case of a 79-year-old woman with stage 3 chronic kidney disease who presented with severe CAP and respiratory failure. Bronchoscopy with bronchoalveolar lavage (BAL) identified CRAB sensitive to tobramycin and levofloxacin but resistant to all Beta-lactams and carbapenems. She was successfully treated with intravenous tobramycin and levofloxacin, followed by oral doxycycline and levofloxacin. Clinical and radiologic resolution was achieved by week 6. This case highlights a rare instance of community-acquired CRAB pneumonia and underscores the importance of BAL-based diagnosis and susceptibility-guided therapy, particularly in high-risk patients.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.